1-3 of 3
Aniket Saha, MD
Close
Sort by
Journal Articles

Analyzing the Efficacy and Design Considerations of VR Environments to Manage Anxiety & Depression in AYA Cancer Patients

Elizabeth H. Cull, MD, Aniket Saha, MD MS, Laura Michelle Stanley, PhD, Vishnunarayan Prabhu, MS, Joshua Biro
Journal: Blood
Blood (2019) 134 (Supplement_1): 3441.
https://doi.org/10.1182/blood-2019-128201
Published: 2019
Journal Articles

Romedepsin (RM), a Histone Deacytelase Inhibitor (HDACi), Significantly Increases the Expression of NKG2D Ligands, MIC A/B, In Pediatric Leukemia/Lymphoma Cells (LL), Resulting In Enhanced In Vitro and In Vivo NK Cytotoxicity In NOD-SCID Mice: Translational Approach for Adoptive NK Cell Targeted Immunotherapy

Prakash Satwani, MD, Aniket Saha, MD, Sejal Bavishi, BS, Frances Zhao, MS, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mitchell S. Cairo, MD
Journal: Blood
Blood (2010) 116 (21): 4297.
https://doi.org/10.1182/blood.V116.21.4297.4297
Published: 2010
Journal Articles

Romedepsin (RM), a HDACi, Significantly Increases the Expression of NKG2D Ligands, MIC A/B, in Leukemia/Lymphoma Cells (LL), in Part through the Glycogen Synthase Kinase-3 (GSK-3) Pathway, Resulting in Enhanced NK Cytotoxicity.

Aniket Saha, MD, Sejal Bavishi, B.S., Frances Zhao, Janet Ayello, MS, MT, Carmella van de Ven, MA, Prakash Satwani, MD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2009) 114 (22): 3027.
https://doi.org/10.1182/blood.V114.22.3027.3027
Published: 2009